A Healthy Novartis Increases Stake in a Rival
Swiss drug company Novartis reports 15 percent rise in fourth-quarter profits, better than expected, and also reveals it has increased its stake in Roche Holding from 32.7 percent to 33.3 percent Novartis's chief executive Dr Daniel Vasella says company has no plans to buy more than one-third of Roche; Swiss rules dictate that buying more than one-third of company would effectively mean beginning of formal takeover bid; Novartis says income rose to $1.36 billion in quarter, while sales rose 21 percent, to $6.73 billion; net income was up 6 percent in 2003, to $5 billion; sales rose 19 percent, to $24.9 billion; photo (M)
